Published August 27, 2026

Multi-Cancer Early Detection Test Guide: Who It Is For and How to Choose

A complete guide to multi-cancer early detection testing, covering who it fits, who it does not, how Core, Me, and 12 differ, how to prepare, and how to read results.

Medically reviewed by Rhonda Collins, FNP-C | Mito Health on August 27, 2026.

A multi-cancer early detection (MCED) test screens for signals of several cancers at once from a single blood draw. It is most useful as an addition to guideline-recommended screening for adults 40 and older, or for people with elevated risk, and it is not a diagnosis. This guide covers who the test fits and who it does not, how the three LucenceINSIGHT panels differ, how to prepare, how long results take, and how to read what comes back. The one thing it will not do is quote prices: those live on the product pages and change over time. For the cost breakdown, see the companion article on multi-cancer blood test cost and how to get one.

Who is a multi-cancer early detection test for?

MCED testing is generally aimed at:

• Adults 40 and older, where cancer risk rises with age, or
• People with elevated risk at any age, such as a relevant family history, or diet and lifestyle factors that raise concern.

The reason the category exists is a real gap. Cancer is the second leading cause of death worldwide per the World Health Organization, and the majority of US cancer deaths come from cancers with no recommended screening test. Deriving from GLOBOCAN 2024 data and the U.S. Preventive Services Task Force list of screenable cancers, over half of US cancer deaths fall outside routine screening. Late diagnosis is common: one analysis found 52.8% of cancers are diagnosed at Stage III or IV (Zeng H et al., Lancet 2021), and five-year survival is generally far higher when cancer is caught early, per NIH National Cancer Institute SEER data. MCED aims to widen the net beyond the few cancers current programs screen for.

Who is it not for?

MCED testing is not appropriate for everyone, and some situations are ruled out because they can interfere with the blood signal the test reads. Subject to your doctor’s judgment, LucenceINSIGHT is generally not a fit if you:

• are pregnant,
• have been in cancer remission for less than 3 years (remission <3 years),
• had surgery, an allogeneic bone-marrow transplant, or a blood transfusion less than 2 weeks before the blood draw (<2 weeks before the draw).

Two more limits matter for anyone considering the test. MCED does not assess inherited or germline cancer risk and is not a substitute for genetic counseling. And it does not detect every cancer: brain tumors, for example, are excluded because they release little ctDNA into the bloodstream. The clinician review step in the ordering flow is where eligibility is checked, so these situations get caught before a draw.

Core vs Me vs 12: which panel?

LucenceINSIGHT comes in three panels that differ by breadth and personalization. Breadth maps to how much of US cancer mortality the targeted cancers account for.

• Core screens for signals associated with 6 cancers that together account for more than half of US cancer mortality: thyroid, breast, pancreatic, colorectal, lung, and liver. It is the essential first screen.
• Me is Core plus 1 to 3 more cancers chosen with your doctor from a curated list, for 7 to 9 cancers total depending on how many you add. It is personalized to your family history and personal risk, and its mortality coverage ranges from 53% to 76% depending on which cancers you add.
• 12 is the comprehensive, gender-specific panel covering 12 cancers, roughly 78% of US cancer mortality. The male and female panels differ in which cancers they include.

Wider is not automatically better. A broader panel screens for more cancers, but prediction is imperfect and every signal still has to translate into a next step you would actually take. Me exists because targeted often beats broad for most people: keep the highest-mortality cancers in Core, then add the ones your risk actually points to. If you are unsure where your risk sits, the Cancer Risk Profile quiz is a quick starting point, and the personalized cancer screening plan after 40 walks through building screening around your own risk.

How does the test work?

From one blood draw, LucenceINSIGHT uses next-generation sequencing to detect circulating tumor DNA (ctDNA) and cancer-associated viral DNA. Machine learning then predicts the likely tissue of origin when a signal is found, so a positive result points toward where to look next rather than just flagging that something looks off. It is performed by a CLIA/CAP-accredited laboratory (Lucence Health Inc.).

In a Lucence validation study across cancer patients at multiple stages (retrospective), overall sensitivity was 80.9% (233 of 288 patients) and specificity was 99.0% (310 of 313 self-declared healthy donors); tumor-localization accuracy was 87.7% overall, with a high-confidence tissue-of-origin prediction possible in 62.4% of cases (Lucence LucenceINSIGHT validation). Keep two caveats attached to those numbers: sensitivity varies by cancer type and stage, so a cancer being included on the panel does not mean it is equally detectable, and detection is generally easier at later stages than at Stage I.

How do you prepare for the blood draw?

Preparation is light:

• No fasting is required.
• Avoid a heavy meal in the 4 hours before your draw.
• The sample is collected in 2 x 10 mL Streck tubes.
• If you are on dialysis, have the blood drawn before your dialysis session.

The order also includes the clinician review that confirms eligibility, so anyone in one of the excluded situations above is identified before the draw.

How long do results take?

Turnaround for LucenceINSIGHT is about 18 working days from sample receipt. Annual testing is commonly advised, on your doctor’s guidance, because risk is not static and a single screen is a snapshot rather than a settled answer.

How do you read the results, and what does a positive mean?

An MCED result is a screening signal, not a diagnosis. That framing drives everything about how to read it:

• A positive or elevated result means a cancer-associated signal was detected, often with a predicted tissue of origin. It is not a diagnosis. The next step is a confirmatory clinical workup that your doctor decides on, which may include imaging or tissue sampling directed by the predicted origin.
• A negative or low result does not mean you are cancer-free. It means no signal was detected on this test at this time. Sensitivity varies by cancer and stage, and some cancers are not covered at all, so continue your guideline-recommended screening either way.
• The test does not assess inherited risk. A result tells you nothing about germline mutations such as BRCA1/2, and it is not a substitute for genetic counseling.

Because MCED is an adjunct, it works best layered on top of proven screening such as mammography, colonoscopy, and low-dose CT for eligible smokers, not as a replacement for any of them.

The Mito difference

With Mito, the whole path is built around telehealth, so you do not have to source your own doctor’s order: choose a panel, a clinician reviews and orders it if appropriate, you get the blood draw, and results return through the telehealth path. For members, an MCED signal does not sit alone. It lands alongside the standard bloodwork and biomarkers Mito already tracks, so the Concierge and your consult can interpret a result in the context of the rest of your health rather than as an isolated report. The Me panel is where that personalization is strongest, because you and your doctor choose the added cancers to match your own risk.

Ready to choose? Start with LucenceINSIGHT Me for the personalized option, or compare Core and 12. Mito also offers the Galleri multi-cancer early detection test as an alternative to compare.

Multi-cancer early detection test questions

Is a multi-cancer early detection test a diagnosis? No. It is a screening test. A positive result needs a confirmatory workup ordered by your doctor, and a negative result does not rule out cancer.

Do I need to fast? No fasting is required. Avoid a heavy meal in the 4 hours before your draw, and if you are on dialysis, draw before your session.

How many cancers does it screen for? Core covers 6 cancers, Me covers 7 to 9 depending on how many you add, and 12 covers 12. More cancers is not automatically better; the right panel depends on your risk.

Does it check for inherited cancer risk? No. MCED does not assess germline or inherited risk and is not a substitute for genetic counseling.

How often should I test? Annual testing is commonly advised on your doctor’s guidance, because risk changes over time and a single screen is a snapshot.

Can I still skip my regular screenings? No. MCED complements guideline-recommended screening such as mammography and colonoscopy. It does not replace them.

Related guides

• What Is a Multi-Cancer Early Detection (MCED) Test?
• Multi-Cancer Blood Test: What It Costs and How to Get One
• Personalized Cancer Screening Plan After 40
• Cancer Antigen 125 (CA-125)

Medical disclaimer

This guide is for informational purposes only. It does not diagnose cancer, recommend a specific test for you, or replace medical care. Multi-cancer early detection is a screening test, not a diagnosis, and it complements rather than replaces guideline-recommended screening. A negative result does not mean you are cancer-free, and a positive result requires confirmatory evaluation ordered by a qualified clinician who considers your symptoms, history, and risk. LucenceINSIGHT is a prescription-only laboratory-developed test and is not FDA-cleared.